Proceeds to be used to continue to advance rigorously designed clinical trials of Armata's high purity phage-based therapeutic candidates LOS ANGELES, March 4, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has entered into a secured credit agreement with Innoviva Strategic Opportun ...

Company Overview - Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections using proprietary technology [3]. Upcoming Presentation - Dr. Mina Pastagia, Chief Medical Officer of Armata, will present at the 6th Annual Bacteriophage Therapy Summit on February 28, 2024, covering the clinical trials and advantages of Armata's bacteriophage candidates [1]. - The presentation will include topics such as the multi-phage cocktail approach for chronic Pseudomonal respiratory infections and the safety of intravenous dosing of Armata's S. aureus phage candidate [1]. Industry Context - The 2024 Bacteriophage Therapy Summit aims to optimize safety, efficacy, and manufacturing of next-generation bacteriophage therapies, with a focus on demonstrating positive clinical data and patient outcomes [2]. - The summit will feature over 90 phage experts and is positioned as a global platform for phage drug developers, emphasizing advancements in clinical and regulatory development, manufacturability, and innovative applications [2].

AmpliPhi Biosciences Corp. (APHB) AmpliPhi Biosciences and C3J Therapeutics Agree to Merge Conference Call January 14, 2018 4:30 PM ET Company Participants Robert Uhl - Westwicke Partners Paul Grint - Chief Executive Officer, AmpliPhi Biosciences Steve Martin - Chief Financial Officer, AmpliPhi Biosciences Todd Patrick - President and Chief Executive Officer, C3J Therapeutics Brian Varnum - Chief Development Officer, C3J Therapeutics Conference Call Participants Joe Pantginis - HC Wainwright Michael Higgins ...